SCHEMBL7836019

SCHEMBL7836019

COC(=O)c1csc(-c2cccc(OCc3ccc(OC)cc3)c2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 1/20 0.53
SMPD1 P17405 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
MAPT P10636 3/20 0.47
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 2/20 0.46
LMNA P02545 2/20 0.46
MAOA P21397 1/20 0.46
ACHE P22303 1/20 0.46
HPGD P15428 1/20 0.46
TP53 P04637 1/20 0.46
IRAK4 Q9NWZ3 2/20 0.46
F9 P00740 1/20 0.46
F10 P00742 1/20 0.46
NPC1 O15118 1/20 0.46
HSP90AA1 P07900 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL847234 0.81 SMPD1 (0.53) SMPD1MAPTALDH1A1KDM4ELMNA
SCHEMBL14481411 0.81 TLR7 (0.63) TLR7MAPTALDH1A1KDM4EMAOA
SCHEMBL848073 0.80 MAOA (0.47) TLR7HDAC3HDAC1HDAC7HDAC8
SCHEMBL846744 0.78 HPGDS (0.59) TLR7HDAC1HDAC8HDAC6ALDH1A1
SCHEMBL5342686 0.78 SMN1; SMN2 (0.60) MAPTALDH1A1KDM4ELMNAHPGD
SCHEMBL7847592 0.77 MAOA (0.45) TLR7HDAC3HDAC1HDAC7HDAC8
SCHEMBL12279458 0.76 MAOA (0.65) TLR7HDAC1HDAC8HDAC6MAPT
SCHEMBL5342437 0.75 ALDH1A1 (0.65) MAPTALDH1A1KDM4ELMNAHPGD
SCHEMBL17489501 0.75 PLA2G4A (0.56) TLR7HDAC3HDAC1HDAC7HDAC8
SCHEMBL29910977 0.74 MAOA (0.61) TLR7HDAC1HDAC8HDAC6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703700-B2 Bimacrocylic HCV NS3 protease inhibitors SEQUOIA PHARMACEUTICALS, INC. (US) 2014-04-22 US disclosed
US-20120141414-A1 Bimacrocylic HCV NS3 Protease Inhibitors SEQUOIA PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120141414-A1 Bimacrocylic HCV NS3 Protease Inhibitors SEQUOIA PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120141414-A1 Bimacrocylic HCV NS3 Protease Inhibitors SEQUOIA PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
WO-2010135748-A1 BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS SEQUOIA PHARMACEUTICALS INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120141414-A1 Bimacrocylic HCV NS3 Protease Inhibitors HAVCR2, CTRC, CTSC TLR7 3855/4885SMPD1 821/4885HDAC3 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.